Healthify Eyes US Market to Power Major Growth and Revenue Expansion

According to various media reports, Healthify, an Indian digital health and wellness startup, is concentrating on the US in an effort to establish the US as its primary source of income. Healthify's co-founder and CEO, Tushar Vashisht, told a media outlet that the company is still in its infancy in terms of business growth, generating only $2 million in recurring income annually. 

He went on to say that the company will reach double-digit millions by the next year and that he believes the brand's US business will be its primary source of income by 2027. As millions of people want to improve their health, nutrition and diet tracking have gained attention from customers who are concerned about their health on a global scale. According to Grand View Research, the size of the global diet and nutrition apps market was estimated at $2.14 billion in 2024 and is projected to increase at a compound annual growth rate (CAGR) of 13.4% from 2024 to 2030, reaching $4.56 billion.

Healthify’s Performance in India

Healthify is concentrating on insurance companies in the United States, but in its home country, it is aiming to form alliances with pharmaceutical companies, then healthcare providers. On the list, insurance companies are at the bottom. In India, Novo Nordisk and Healthify announced a collaboration for a patient support initiative. Originally a calorie-tracking software, the company is now making significant investments to provide proxy support to patients taking GLP-1 medications for weight loss.

The GLP-1 hormone, which regulates blood sugar and hunger, is mimicked by a class of medications known as GLP-1 (glucagon-like peptide-1) agonists. Globally, Goldman Sachs projects that the market for these medications will grow to $95 billion by 2030. However, sustaining profitability continues to be the major objective for Healthify's Indian company. "Hopefully, we'll have most of the months as profitable this year," Vashisht stated, adding he is confident that the company will be "cash flow positive" the next year.

Healthify’s Business Strategy for the US

The corporation has reallocated resources and refocused all of its attention on the US market as a result of the heightened interest. According to Vashisht, the company's global ambitions will receive the majority of the brand's engineering product and tech experience. The US receives a large portion of the company's research expenditures.

To expand its presence in the US, Healthify is trying to work with insurance providers in the country, as well as organisations that offer reimbursement for certified dieticians as a service. There, a large portion of healthcare, including nutrition and diet monitoring, is dependent on insurance. Healthify can supply its consumers with the services of qualified dieticians, which are covered by their insurance service provider, through a relationship such as the reimbursement service.

"Growth and our go-to market in the US will be driven by these partnerships," Vashisht stated. It's also teaming with dietician providers to help reinforce its company and is in the midst of discussing with numerous companies, including the dietician startup Berry Street, which raised $50 million in its Series B round in February of this year from Goldman Sachs at a $500 million valuation. Additionally, the business plans to someday provide HealthifyRx, its premium weight loss product, to the United States.

This month, Healthify's entire software platform will launch. It had already soft-launched its calorie-counting app, Snap, in the United States. Its AI-assisted coaching programme was introduced in March, and its AI-assisted continuous glucose monitoring product was introduced in August.